Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ZyVersa Therapeutics, Inc. - Common Stock (NQ: ZVSA )

0.1310 +0.0011 (+0.85%)
Streaming Delayed Price Updated: 2:46 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ZyVersa Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 2nd Annual Kidney Conference to be Held Virtually on July 25, 2023
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress
From ZyVersa Therapeutics
Via GlobeNewswire
European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD)
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target
From ZyVersa Therapeutics
Via GlobeNewswire
European Patent Office to Grant ZyVersa Therapeutics’ Patent Application for Cholesterol Transport Mediator™ VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Changes to ZyVersa’s Board of Directors
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in A.G.P.’s Virtual Healthcare Conference
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics, Inc. Announces Pricing of $11.0 Million Public Offering
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100
From ZyVersa Therapeutics
Via GlobeNewswire
Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV
Via ACCESSWIRE
ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics’ CEO, Stephen C. Glover to Appear on Benzinga 'All Access'
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Planet MicroCap Showcase
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Article Published in Brain Pathology Addressing Inflammasome Signaling Proteins in Alzheimer’s Disease
From ZyVersa Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.